Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenetic Biosciences (XBIO) Change in Receivables (2023 - 2025)

Xenetic Biosciences' Change in Receivables history spans 7 years, with the latest figure at -$780067.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 433.55% year-over-year to -$780067.0; the TTM value through Dec 2025 reached -$255660.0, down 40.57%, while the annual FY2025 figure was -$255660.0, 40.57% down from the prior year.
  • Change in Receivables reached -$780067.0 in Q4 2025 per XBIO's latest filing, down from $372507.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $442496.0 in Q2 2023 to a low of -$876734.0 in Q4 2023.
  • Average Change in Receivables over 3 years is -$32483.3, with a median of $162932.5 recorded in 2023.
  • The largest YoY upside for Change in Receivables was 170.51% in 2025 against a maximum downside of 433.55% in 2025.
  • A 3-year view of Change in Receivables shows it stood at -$876734.0 in 2023, then skyrocketed by 126.67% to $233866.0 in 2024, then crashed by 433.55% to -$780067.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Change in Receivables are -$780067.0 (Q4 2025), $372507.0 (Q3 2025), and $260234.0 (Q2 2025).